LMRI — Lumexa Imaging Holdings, Inc. Common Stock

Lumexa Imaging Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Consolidated Revenues: $253 million, up 3% year-over-year.
• System-wide Revenue Growth: 4%, driven by volume (2/3) and rate increases (1/3).
• Advanced Modalities Growth: 7% year-over-year, with PET growing 23.1% and MRI 8.2%.
• Adjusted EBITDA: $51.2 million, flat compared to $51.1 million in Q1 2025, reflecting seasonal and weather-related impacts.
• Net Income: $2 million, compared to a net loss of $8 million in the prior year.
• GAAP EPS: $0.02; Adjusted EPS: $0.18.
• Free Cash Flow: Negative $2 million, an improvement of $13 million year-over-year.

2. Strategic Updates and Business Highlights

• De Novo Openings: Two new centers opened in South Carolina and Florida; targeting 8-10 de novos annually.
• Acquisitions: Completed two acquisitions, including a site in Pennsylvania as part of a joint venture with UPMC.
• AI Initiatives: Continued rollout of AI-powered solutions, particularly in breast arterial calcification, with strong patient uptake.
• Joint Ventures: Active discussions with multiple health systems to expand partnerships and enhance outpatient imaging capacity.
• Technology Integration: Ongoing deployment of FastScan software across MRI machines, with a goal of 66-67% adoption by year-end.

3. Forward Guidance and Outlook

• Revenue Guidance: Expected to be between $1.045 billion and $1.097 billion for the full year 2026.
• Adjusted EBITDA Guidance: Projected between $234 million and $242 million, with anticipated growth in the second half of the year.
• Adjusted EPS Guidance: Expected to range from $0.71 to $0.77 per share.
• Seasonal Performance: Anticipated gradual ramp-up in adjusted EBITDA throughout the year, with Q4 expected to contribute significantly to annual performance.

4. Bad News, Challenges, or Points of Concern

• Weather Impact: Q1 results were negatively affected by multiple weather events, resulting in an estimated $4 million EBITDA impact.
• Seasonality Effects: Increased seasonality observed compared to previous years, with a shift in payer mix from commercial to government payers.
• Cybersecurity Incident: A vendor experienced a data breach involving Lumexa data, though management stated it does not have a material impact on business or financial results.
• Fixed Cost Structure: The company's partially fixed cost structure led to margin pressure during periods of lower patient volume.

5. Notable Q&A Insights

• UPMC Joint Venture: Management expressed optimism about accelerating growth through the UPMC partnership, with plans for additional de novos.
• Volume Recovery: Advanced modalities have rebounded more quickly than routine scans, which are expected to ramp up in the coming quarters.
• CapEx and Cash Flow: Anticipated CapEx of $5-7 million per quarter, with expectations for free cash flow to improve significantly in the second half of the year.
• Payer Mix Stability: No significant changes in the reimbursement landscape were noted, with seasonal shifts being the primary factor affecting payer mix in Q1.

Overall, Lumexa Imaging reported a solid start to 2026, with strategic growth initiatives underway, though faced with challenges from weather impacts and a cybersecurity incident. The company remains optimistic about its growth trajectory and financial outlook for the year.